Using the Consortium of Investigators of Modifiers of BRCA1/2 as a data source for their analysis, investigators sought to characterize the spectrum of cancers diagnosed in men and identify differences between BRCA1 and BRCA2 carriers. Men included in the study (n = 6902) were older than 18 years and carried a pathogenic or likely pathogenic BRCA1 or BRCA2 variant. Read more . . .
Men who are carriers of a BRCA2 pathogenic variant were more likely to develop breast, prostate, and pancreatic cancers than patients harboring BRCA1, according to an analysis of male and female carriers of BRCA1/2 pathogenic variants. These data may represent an unmet need in screening guidelines for this patient population.